dc.contributor.author | Val-Blasco, Almudena | |
dc.contributor.author | Zaragoza Sánchez, Carlos | |
dc.contributor.author | Fernández-Velasco, María | |
dc.date.accessioned | 2022-09-12T11:56:53Z | |
dc.date.available | 2022-09-12T11:56:53Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 2452-302X | spa |
dc.identifier.uri | http://hdl.handle.net/10641/3092 | |
dc.description.abstract | Highlights
•
Administration of BML-111, a stable LXA4 analog, protects against cardiac dysfunction by avoiding Ca2+ mishandling induced by autoimmune myocarditis in a mouse model.
•
Beneficial effects of the SPMs on intracellular Ca2+ handling are mainly caused by a regulation of SERCA2A by NRF2.
•
Cardiac tissue obtained from individuals diagnosed with myocarditis, compared with healthy myocardium tissues, displayed depressed mRNA levels of ATP2A2 (SERCA2A) and NF2L2 (NRF2). | spa |
dc.language.iso | eng | spa |
dc.publisher | JACC: Basic to Translational Science | spa |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.subject | Calcium handling | spa |
dc.subject | Myocarditis | spa |
dc.subject | Pro-resolving mediators | spa |
dc.title | Specialized Proresolving Mediators Protect Against Experimental Autoimmune Myocarditis by Modulating Ca2+ Handling and NRF2 Activation. | spa |
dc.type | journal article | spa |
dc.type.hasVersion | AM | spa |
dc.rights.accessRights | open access | spa |
dc.description.extent | 3992 KB | spa |
dc.identifier.doi | 10.1016/j.jacbts.2022.01.009 | spa |
dc.relation.publisherversion | https://www.sciencedirect.com/science/article/pii/S2452302X22000304?via%3Dihub | spa |